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During colitis, activation of two inflammatory T cell subsets, Th17 and Th1 cells, promotes ongoing intestinal inflammatory
responses. n-6 polyunsaturated fatty acid- (PUFA-) derived eicosanoids, such as prostaglandin E
2
(PGE
2
), promote Th17 cell-
mediated inflammation, while n-3 PUFA antagonize both Th17 and Th1 cells and suppress PGE
2
levels. We utilized two genetic
mouse models, which differentially antagonize PGE
2
levels, to examine the effect on Th17 cells and disease outcomes in
trinitrobenzene sulfonic acid- (TNBS-) induced colitis. Fat-1 mice contain the 𝜔3 desaturase gene from C. elegans and synthesize
n-3 PUFA de novo, thereby reducing the biosynthesis of n-6 PUFA-derived eicosanoids. In contrast, Fads1 Null mice contain a
disrupted Δ5 desaturase gene and produce lower levels of n-6 PUFA-derived eicosanoids. Compared to Wt littermates, Fat-1 and
Fads1 Null mice exhibited a similar colitic phenotype characterized by reduced colonic mucosal inflammatory eicosanoid levels
and mRNA expression of Th17 cell markers (IL-17A, ROR𝛾𝜏, and IL-23), decreased percentages of Th17 cells and, improved colon
injury scores (𝑃 ≤ 0.05). Thus, during colitis, similar outcomes were obtained in two genetically distinct models, both of which
antagonize PGE
2
levels via different mechanisms. Our data highlight the critical impact of n-6 PUFA-derived eicosanoids in the
promotion of Th17 cell-mediated colonic inflammation.
1. Introduction
Inflammatory bowel disease (IBD) manifests as two clinical
conditions, ulcerative colitis (UC) and Crohn’s disease (CD).
The induction and persistence of chronic inflammation
during IBD is attributed to the activation of two inflammatory
T cell subsets (Th17 and Th1 cells) and production of their
signature cytokines, IL-17 and IFN𝛾, respectively [1–4]. The
role of Th17 cells in the pathogenesis of IBD has been
documented in humans with active disease [5–7] and in
mouse models in which disease severity was reduced by
blockade or deficiency of IL-23 and/or IL-17 [8, 9].
A recent case-control study found that high intakes of
n-6 polyunsaturated fatty acids (PUFA) increased the risk
of developing UC [10] which was attributed, in part, to
the immunomodulatory effects of arachidonic acid- (AA-)
derived eicosanoids [11]. In IBD patients (CD and UC)
increased levels of AA and its eicosanoid metabolites, such as
PGE
2
, leukotriene B
4
(LTB
4
), and thromboxane B
2
(TXB
2
),
were found in themucosa of the gastrointestinal tract [12–17].
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In UC patients, the concentration of PGE
2
increased in
proportion to the degree of mucosal injury or disease severity
[17]. Moreover, in IBD patients, the combination of PGE
2
,
IL-23, and IL-1𝛽 works synergistically to enhance IL-17A
secretion from CD161+ CD4+ T cells [18] which infiltrate the
gastrointestinal tract [19–21]. In the trinitrobenzene sulfonic
acid- (TNBS-) inducedmouse colitis model, which induces T
cell-mediated immune responses within the colonic mucosa
[22] and is driven by inflammatory Th17 cells [23], both
serum and colonic mucosal PGE
2
levels were elevated [24].
PGE
2
was shown to exacerbate colonic inflammatory pro-
cesses and colitis severity in thismodel through the activation
of the IL-23/IL17 axis and by increasing local Th17 cell num-
bers [25]. Through alterations in the cytokine microenviron-
ment, PGE
2
can influence inflammatory T cell development
directly by skewing naı¨ve T cell differentiation and effector
function toward the production of proinflammatory Th17
and Th1 cell subsets [18, 26–29] and indirectly by inducing
antigen presenting cells to favor IL-23 production [25, 30,
31], thereby promoting the differentiation and maintenance
of Th17 cells. Other n-6 PUFA-derived eicosanoids have
also been shown to promote Th17 cell development [32],
thereby demonstrating partial functional redundancy in the
immunomodulatory effects of the AA-derived eicosanoid
profile. Collectively, these data indicate that AA-derived
eicosanoids may drive the activation of Th17 cells during
IBD and any treatment strategy designed to antagonize their
mucosal levels could reduce Th17 cell activation and the
severity of the disease phenotype.
Fish oil (FO) derived long chain n-3 PUFA exert anti-
inflammatory effects [33–35] and have been shown to
enhance remission of chronic intestinal inflammation [36].
Moreover, an estimated 50% of IBD patients utilize self-
prescribed oral complementary alternative medicines/diets,
such as FO [37]. Dietary n-3 PUFA accumulate in cell
membranes, partly at the expense of AA, thereby reduc-
ing the available substrate for the synthesis of AA-derived
eicosanoids [38–41] while concomitantly serving as sub-
strates for the production of n-3 PUFA-derived anti-
inflammatory resolvins, docosatrienes, and neuroprotectins
[42]. Further, n-3 PUFA have been demonstrated to reduce
splenic CD4+ T cell ex vivo polarization intoTh1 [43, 44] and
Th17 cells [45]. Therefore, n-3 PUFA may suppress colitis-
associated Th17 cell activation, in part, by reducing mucosal
AA-derived eicosanoid levels. To test this hypothesis, we
utilized two genetic mouse models which antagonize AA-
derived eicosanoid production: (i) the Fat-1 transgenicmouse
which produces long chain n-3 PUFA de novo [46] and
exhibits reduced colonic AA-derived eicosanoid levels [47]
and (ii) the Fads1 Null mouse, which exhibits systemic
disruption of the Fads1 (Δ5 desaturase) gene, reciprocally
altering the tissue level of dihomo-𝛾-linolenic (DGLA) and
AA, resulting in decreasedAA-derived eicosanoid levels [48].
In this study, we determined the effect of antagonizing AA-
derived eicosanoids on local [colon and mesenteric lymph
node (MLN)] and systemic (splenic) levels of the relevant
CD4+ T cell effector subsets (Th17, Th1, Th2, and Tregs) and
Th17 cell-mediated colonic cytokine expression in response
to TNBS-induced colitis.
2. Materials and Methods
2.1. Animals and Diets. Fads1 and Fat-1 transgenic mice, both
on a C57BL/6 background, were generated in collaboration
with the Texas Institute for Genomic Medicine (Texas A&M
University) and Dr. Jing Kang (Harvard University), respec-
tively. Fads1 knockout mice [genotypes: wild-type (Wt), het-
erozygous (Het), and null (Null)] represent a Δ5 desaturase
knockout strain that produces AA deficiency without the
underlying complication of essential fatty acid deficiency [i.e.,
linoleic acid (LA) or DGLA] [48]. Fat-1 transgenic mice
(genotypes: Wt and Fat-1) synthesize long chain n-3 PUFA de
novo [46]. Littermate specific pathogen-free male and female
mice from both strains were genotyped, phenotyped, and
housed as previously described [46–48]. All mice were fed
a commercial 10% safflower oil diet (D03092902R; Research
Diets, New Brunswick, NJ, USA), wherein GC fatty acid anal-
ysis of the diet confirmed that it is free of AA and contained
trace levels of n-3 PUFA (0.17% 𝛼-linolenic acid) but was
adequate in all other nutrients. All procedures adhered to
U.S. Public Health Service Policy and were approved by the
Institutional Animal Care and Use Committee at Texas A&M
University.
2.2. Colitis Induction and Histological Scoring. Colonic
inflammation was induced by exposure to 2,4,6-trinitro-
benzene sulfonic acid (TNBS; Sigma Aldrich, St. Louis,
MO, USA) as previously described [49]. In brief, mice were
individually housed and 100 𝜇L of a 1% (w/v) presensitizing
dosage of TNBS dissolved in a 4 : 1 volume ratio of acetone
and olive oil (Azienda, Florence, Italy) was applied topically
onto a shaved 1.5 × 1.5 cm field between the shoulders. The
site was selected to prevent the animals from ingesting the
TNBS which could induce oral tolerance [49]. After 7 d, mice
were anesthetized with isoflurane to effect and were under
anesthesia for ≤5min during which time a 100𝜇L enema
containing 2.5% (w/v) TNBS in a 1 : 1 volume ratio of water
and absolute ethanol was administered. Saline control mice
were exposed to the presensitization vehicle topically (4 : 1
volume ratio of acetone and olive oil) followed 7 d later by a
100 𝜇L saline enema. All mice were sacrificed 3 d after TNBS
enema by CO
2
asphyxiation. Colons were excised (distal to
the cecum and proximal to the anus) and flushed with sterile
PBS and the mucosa was scraped from one longitudinal
colon half for gene expression analysis.Theother longitudinal
colon half was fixed in 4% paraformaldehyde, Swiss-rolled,
paraffin embedded, and stained with hematoxylin and eosin.
The degree of colon injury (score 0–3 per colon region, i.e,
proximal,middle, and distal) was graded in a blindedmanner
by a board-certified pathologist (B. Weeks) in accordance
with the criteria outlined previously [47].
2.3. Flow Cytometry Analysis of T Cell Subsets. Splenic and
MLN mononuclear cells were isolated by lympholyte-M
enrichment (Cedarlane, Burlington, NC, USA) as described
[50]. Colonic tissues were digested using Type IV collagenase
(SigmaAldrich) as described elsewhere [51] and lymphocytes
were enriched over 70/45% Percoll gradient (Sigma Aldrich).
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Surface and intracellular stainingwere performed as reported
previously [45, 52]. Cells were surface-stained with APC-
anti-CD4 (clone L3T4, eBioscience, San Diego, CA, USA)
followed by intracellular detection of PE-anti-FOXP3 (clone
FJK-16s), PE-anti-IL-17A (clone eBio17B7), PE-anti-IFN𝛾
(clone XMG1.2), or PE-anti-IL-4 (clone 11B11) (eBioscience).
Isotype controls utilized were PE-IgG2a𝜅, PE-IgG1𝜅, and
APC-IgG2b𝜅 (eBioscience). Flow cytometric analysis was
conducted using a BD Accuri C6 flow cytometer (BD Bio-
science, San Jose, CA, USA).
2.4. RNA Isolation and Measurement of mRNA Expression.
RNA was isolated from colon mucosal scrapings using
the RNA 4-PCR kit (Ambion/Life Technologies, Grand
Island, NY, USA). Real-time RT-PCR was used to quantify
mRNA expression and amplification was performed using
the Taqman Universal PCR master mix and Taqman gene
expression kits (Applied Biosystems/Life Technologies,
Grand Island, NY, USA) were used for amplification
of IL-1𝛽 (Mm00434228 m1), IL-6 (Mm00446190 m1),
IL-17A (Mm00439618 m1), IL-17F (Mm00521423 m1),
IL-21 (Mm00517640 m1), IL-22 (Mm01226722 g1), IL-23
(Mm00518984 m1), IL23R (Mm 00519943 m1), IFN𝛾
(Mm01168134 m1), IL-27 (Mm00461162 m1), TNF𝛼
(Mm00443260 g1), CCL2 (MCP-1, Mm00441242 m1),
IL-4 (Mm00445259 m1), IL-10 (Mm00439614 m1), TGF𝛽1
(Mm01178820 m1), Rorc (ROR𝛾𝜏, Mm01261022 m1), Tbx21
(T-bet, Mm00450960 m1), FOXP3 (Mm00475162 m1),
CCL20 (Mm01268754 m1), and CCR6 (Mm99999114 s1).
Amplification of mRNA (fluorescence) was recorded over 40
cycles and the corresponding cycle numbers (Ct) were used
to calculate mRNA expression according to the calculation:
2(40−Ct). Target gene expression was normalized to ribosomal
18S expression (Mm03928990 g1).
2.5. Colonic Mucosal Eicosanoid Profiling. Eicosanoids were
extracted from colonic scraped mucosa from TNBS-treated
Fat-1 and Fads1 mice as previously described [47, 48, 53].
Liquid chromatography/tandemmass spectroscopic analyses
were performed using a QuattroUltima mass spectrometer
(Waters, Milford, MA, USA) equipped with an Agilent 1100
binary pump high-performance liquid chromatography sys-
tem (Agilent Technologies, Santa Clara, CA, USA) according
to a modified version of the method of Yang et al. [53].
Eicosanoids of interest were chromatographically separated
using a Luna 3𝜇m phenyl-hexyl 4.6 × 100mm analytic
column (Phenomenex, Torrance, CA,USA) [48]. Eicosanoids
were detected and quantified by multiple reaction mode
monitoring of the transitions 𝑚/𝑧 as described elsewhere
[48, 54].
2.6. Statistics. The predetermined upper limit of probability
for statistical significance throughout this investigation was
𝑃 ≤ 0.05, and analyses were conducted using the SAS system
for Windows Version 9.0 (SAS Institute, Cary, NC, USA).
Data were analyzed by either one-way ANOVA or two-way
ANOVA (main effects: genotype and treatment) followed,
if justified, by testing using Least Squares Means. Data sets
Table 1: Colonicmucosal eicosanoid and cannabinoid profiles inWt
and Fat-1 TNBS-treated mice1.
Eicosanoid
(ng/mg protein) Wt Fat-1
PGE1 0.68 ± 0.16 1.00 ± 0.35
PGE2 13.79 ± 3.46 7.50 ± 1.79
∗
PGE3 0.00 ± 0.00 0.24 ± 0.03
∗
PGD2 44.37 ± 2.09 23.18 ± 5.69
∗
PGF
2𝛼
4.16 ± 0.64 2.40 ± 0.59∗
6-keto-PGF
1𝛼
3.65 ± 0.73 2.05 ± 0.35
TXB2 1.02 ± 0.16 0.85 ± 0.28
13-PGE1 0.02 ± 0.01 0.00 ± 0.00
13-PGE2 11.33 ± 2.36 7.68 ± 1.27
13-HODE 12.29 ± 2.68 8.33 ± 0.87
5-HETE 1.01 ± 0.18 0.93 ± 0.35
12-HETE 7.74 ± 2.22 8.40 ± 3.69
15-HETE 0.97 ± 0.13 0.50 ± 0.15∗
AEA 44.10 ± 3.89 19.97 ± 6.35∗
2-AG 0.50 ± 0.05 0.24 ± 0.03∗
1Mean values ± SEM of TNBS-treated Fat-1 mice (𝑛 = 4-5/genotype)
and values marked with an asterisk differ from Wt (𝑃 ≤ 0.05). PG,
prostaglandin; TX, thromboxane; 13-PGE1, 13,14-dihydro 15-keto-PGE1; 13-
PGE2, 13,14-dihydro 15-keto-PGE2; HODE, hydroxyl-octadecadienoic acid;
HETE, hydroxyl-eicosatetraenoic acid; AEA, arachidonoyl ethanolamine;
and AG, arachidonoyl glycerol.
not exhibiting a normal distribution were analyzed using the
Kruskal-Wallis test (𝜒2 approximation) followed, if justified,
by the statistical probability outcome (𝑃 ≤ 0.05) using
Wilcoxon two-sample testing.
3. Results
3.1. Colonic Mucosal Inflammatory AA-Derived Eicosanoid
Profile Is Antagonized in Fat-1 and Fads1 Null Mice. The
colonic mucosal eicosanoid profiles from TNBS-treated
Fat-1 (Table 1) and Fads1 (Table 2) mice are shown. In
Fat-1 mice, colonic mucosal levels of n-6 PUFA-derived
eicosanoids, specifically PGE
2
, prostaglandins (PG) D
2
and
F
2𝛼
, 15-hydroxy-eicosatetraenoic acid (HETE), arachidonoyl
ethanolamine (AEA), and arachidonoyl glycerol (AG), were
reduced significantly, whereas the n-3 PUFA-derived PGE
3
was increased compared toWt (𝑃 < 0.05). In Fads1Nullmice,
increased levels of PGE
1
and decreased levels PGE
2
, D
2
, F
𝛼
,
thromboxane (TX) B
2
, 5-HETE, AEA, and 2AG (𝑃 < 0.05)
were observed compared toWt littermates. Collectively, these
data demonstrate that the local inflammatory (n-6 PUFA-
derived) eicosanoid profile in response to TNBS-induced
colitis is antagonized in both genetic mouse models via two
differentmechanisms, that is, by increasing n-3 PUFAcontent
in Fat-1 mice and by inducing AA deficiency in Fads1 Null
mice, as seen previously [47, 48].
3.2. Fat-1 Mice Are More Resistant to TNBS-Induced Colon
Injury. Body weight and colon length at the time of sacrifice
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Table 2: Colonic mucosal eicosanoid and cannabinoid profiles in
Fads1 TNBS-treated mice1.
Eicosanoid
(ng/mg protein) Wt Het Null
PGE1 1.91 ± 1.09
∗ 1.87 ± 0.50∗ 16.36 ± 6.88‡
PGE2 15.70 ± 4.92
∗ 14.19 ± 1.66∗ 1.92 ± 0.77‡
PGE3 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
PGD2 43.12 ± 4.51
∗ 39.14 ± 2.51∗ 1.38 ± 0.06‡
PGF
2𝛼
5.94 ± 0.98∗ 4.15 ± 0.57∗ 0.11 ± 0.03‡
6-keto-PGF
1𝛼
3.78 ± 0.98∗ 3.00 ± 0.74∗ 0.41 ± 0.11‡
TXB2 1.08 ± 0.23
∗ 1.26 ± 0.21∗ 0.17 ± 0.02‡
13-PGE1 0.11 ± 0.05
∗ 0.07 ± 0.03∗ 0.78 ± 0.14‡
13-PGE2 14.34 ± 1.62
∗ 7.71 ± 0.94‡ 0.69 ± 0.09§
13-HODE 14.05 ± 2.63 23.18 ± 7.63 9.25 ± 1.67
5-HETE 1.04 ± 0.16∗ 2.65 ± 1.35∗ 0.12 ± 0.01‡
12-HETE 6.47 ± 1.88∗ 47.66 ± 12.84‡ 2.57 ± 1.40∗
15-HETE 1.06 ± 0.10 3.04 ± 1.50 0.11 ± 0.02
AEA 0.59 ± 0.04∗ 0.52 ± 0.07∗ 0.04 ± 0.00‡
2-AG 34.88 ± 6.74∗ 56.17 ± 12.53∗ 2.32 ± 0.57‡
1Mean values ± SEM of TNBS-treated Wt, Het, and Null Fads1 mice (𝑛 =
5/genotype). Values not sharing a superscript symbol differ (𝑃 ≤ 0.05). PG,
prostaglandin; TX, thromboxane; 13-PGE1, 13,14-dihydro 15-keto-PGE1; 13-
PGE2, 13,14-dihydro 15-keto-PGE2; HODE, hydroxyl-octadecadienoic acid;
HETE, hydroxyl-eicosatetraenoic acid; AEA, arachidonoyl ethanolamine;
and AG, arachidonoyl glycerol.
are shown in Supplemental Table 1 (see SupplementaryMate-
rial available online at http://dx.doi.org/10.1155/2014/917149).
Compared to saline controls, TNBS-treated mice exhibited
lower body weights and colon shortening, but they did
not differ between genotypes (𝑃 > 0.05). The degree of
colon injury following exposure to TNBS was assessed based
on colonic histological changes in a blinded manner by a
board-certified pathologist (B. Weeks). Representative distal
colon images from Wt and Fat-1 saline control and TNBS-
treated mice are shown (Figures 1(a)–1(c)).The saline control
treatment did not induce colonic damage and both Wt and
Fat-1 mice exhibited an injury score of 0 in all regions of the
colon. In TNBS-treated mice, injury scores were lower in the
proximal and middle regions of the colon compared to the
distal colon; however, they did not differ betweenWt and Fat-
1mice (proximal colon,𝑃 = 0.45, andmiddle colon,𝑃 = 0.54,
results not shown). However, within the distal colon (site of
TNBS administration via rectal enema), the degree of colonic
injury was significantly reduced in Fat-1 mice compared to
Wt (𝑃 = 0.05, Figure 1(d)). This outcome is consistent with
the TNBS model exerting the majority of histopathological
damage within the distal colon [55] and with the ability of n-
3 PUFA to enhance the resolution of inflammatory processes
and reduce colonic injury by promoting mucosal repair [47,
56].
3.3. Colitis-Associated Changes in CD4+ T Cell Subsets in
Local and Systemic Anatomical Sites in Wt and Fat-1 Mice.
Following the induction of colitis, the effect of n-3 PUFA
on the resident CD4+ T cell effector subset populations
(i.e., Th1, Th2, Th17, and Treg) was documented both locally
(colon lamina propria and MLN) and systemically (spleen).
Representative dot plots for T cell subsets isolated from
Wt TNBS-treated colon, MLN, and spleen are shown in
Supplemental Figure 1. In all tissue sites, TNBS exposure
increased the percentage of all CD4+ T cell subsets compared
to the saline control group (treatment: 𝑃 < 0.05, Figures
2–4). Within the colon, the percentages of proinflammatory
Th17 and Th1 cells were reduced in Fat-1 mice compared
to Wt (𝑃 < 0.05, Figures 2(a) and 2(b)), whereas the
percentages of Th2 and Treg cells did not differ between
groups (𝑃 > 0.05, Figures 2(c) and 2(d)). In the MLN, which
drains and is anatomically proximal to the inflamed colon,
the percentages of both Th17 and Th1 cells were reduced in
Fat-1mice compared toWt (𝑃 < 0.05) (Figures 3(a) and 3(b)),
whereas Treg andTh2 cells were unaffected (𝑃 > 0.05, Figures
3(c) and 3(d)). In the spleen, only the percentage ofTh17 cells
was reduced in the Fat-1 mouse (𝑃 < 0.05) compared to Wt
(Figure 4(a)). SplenicTh1, Th2, and Treg cell populations did
not differ between groups (𝑃 > 0.05, Figures 4(b)–4(d)).
Collectively, these data demonstrate that proinflammatory
Th17 and Th1 cells are selectively antagonized by n-3 PUFA
in both local and systemic sites during colitis.
3.4. The Colonic Mucosal Cytokine Microenvironment Is
Modified in a Manner Consistent with Reduced Th17 Cell
Activation in Fat-1 Mice. To gain insight into how effector T
cell populations are changing in response to TNBS-induced
colitis, gene expression of critical transcription factors and
cytokines that make up the inflammatory colonic milieu
were assessed in both Wt and Fat-1 TNBS-treated mice
(Table 3). Colonic mRNA expression of ROR𝛾𝜏, the master
transcription factor that directs both the differentiation of
Th17 cells and the expression of hallmark Th17 cytokines
[57], was reduced significantly in Fat-1 mice (𝑃 = 0.03).
Conversely, n-3 PUFA had no significant effect on the mRNA
expression of other key transcription factors associated with
other T cell subsets, namely, Foxp3 (Tregs) and T-bet (Th1
cells) (𝑃 > 0.05). Gene expression of the Th17 cell signature
cytokine, IL-17A, was decreased significantly in the Fat-1
mouse versus Wt (𝑃 = 0.04), whereas IL-17F and IL-22 did
not differ between groups (𝑃 > 0.05). Additionally, mRNA
expression of IL-21, which promotes Th17 cell differentiation
and proliferation [58, 59] and controls both Th1 and Th17
cell responses [2, 60–62], was reduced in the Fat-1 mouse
(𝑃 = 0.01), consistent with the reduced percentage ofTh1 and
Th17 cells in the colon lamina propria (Figures 2(b) and 2(c)).
Colonic mRNA expression of IL-23 showed a trend towards a
significant reduction in the Fat-1mouse (𝑃 = 0.06), whereas
the expression of IL-23R did not differ between groups
(𝑃 = 0.95). Interestingly, n-3 PUFA significantly upregulated
mRNA expression of IL-27 (𝑃 = 0.04), a key cytokine that
has been shown to antagonizeTh17 cell development [60, 62].
Consistent with the anti-inflammatory effects of n-3 PUFA
[33–35], colonic mRNA expression of IL-10 was upregulated
in the Fat-1 mouse (𝑃 = 0.04), whereas TGF𝛽1 expression
was unaffected (𝑃 = 0.44). Fat-1 mRNA levels of classic
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Figure 1: The degree of distal colon histological injury/damage in Fat-1 and Wt TNBS-treated mice (𝑛 = 8-9/genotype). ((a) and (b))
Representative images (100x magnification, scale bar = 100 𝜇m) of TNBS-treated Fat-1 and Wt mice, (c) Wt saline control treated (injury
score = 0) distal colons, and (d) injury scores (0–3) in the distal colon fromWt and Fat-1 TNBS-treatedmice, respectively. Data were analyzed
using the Kruskal-Wallis test (𝑃 ≤ 0.05). Median values are shown and significant differences between genotypes are marked with an asterisk
(𝑃 ≤ 0.05).
inflammatory cytokines (IL-1𝛽 and TNF𝛼) and chemokines
(MCP-1) were reduced compared to Wt levels (𝑃 < 0.05),
whereas colonic mRNA levels of IL-6, IFN𝛾, and IL-4 did not
differ between genotypes (𝑃 > 0.05).
3.5. TNBS Colitis Induced Colon Injury Is Reduced in Fads1
Null Mice. The degree of TNBS-induced colon injury was
assessed histologically in Fads1Wt,Het, andNullmice (repre-
sentative distal colon images, Figures 5(a)–5(c)). Histological
injury scores were 0 throughout the colon in saline control
treated mice from all three Fads1 genotypes. Within TNBS-
treatedmice, the degree of colon injury did not differ between
genotypes in the proximal (𝑃 = 0.10) and middle (𝑃 = 0.31)
regions of the colon. However, distal colon injury scores were
reduced significantly in Fads1Nullmice compared to bothWt
andHetmice (𝑃 = 0.04) (Figure 5(d)). Colon length and final
body weights were lower in TNBS-treated mice compared to
saline controls but did not differ between genotypes (𝑃 >
0.05) as shown in Supplemental Table 2. These data suggest
that antagonizing colon mucosal eicosanoid levels via AA
deficiency reduces the severity of colon histological structural
damage induced during TNBS colitis.
3.6. Changes in Splenic T Cell Subsets in the Fads1Mouse. Due
to limitations in mouse numbers and the necessity to pool
colons to obtain sufficient cells for analysis, quantification
of T cell subsets in the colon and MLN was not possible.
Therefore, changes in systemic T cell subsets (i.e., Th1, Th2,
Th17, and Treg) following exposure to TNBSwere determined
in the spleen and representative dot plots are shown in Sup-
plemental Figure 2. As expected, TNBS treatment increased
all splenic CD4+ T cell subsets compared to saline controls
(𝑃 < 0.05). The percentages of splenic Th17 and Th1 cells
were reduced in Fads1 Nullmice compared to both Wt and
Het mice (𝑃 < 0.05, Figures 6(a) and 6(b)). Interestingly, the
percentage of splenic Th2 cells was also reduced in the Fads1
Null mouse compared to both Wt and Het TNBS-treated
mice (𝑃 = 0.04, Figure 6(c)), whereas splenic Tregs were
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Figure 2: Percentage of colon lamina propria CD4+ T cell subsets in Wt and Fat-1 TNBS-treated mice (black bars, 𝑛 = 8–16 pooled
samples/genotype comprised of 2-3 colons) and saline controls (grey bars, 𝑛 = 4 pooled samples/genotype). (a) Th17 cells (CD4+ IL-17A+),
(b)Th1 cells (CD4+ IFN𝛾+), (c)Th2 cells (CD4+ IL-4+), and (d) Tregs (CD4+ Foxp3+). Data were analyzed by two-way ANOVA (main effects:
genotype and treatment); bars represent means ± SEM. Bars not sharing a symbol differ (𝑃 ≤ 0.05).
unaffected (Wt versus Null, 𝑃 > 0.05, Figure 6(d)).There was
no difference between Wt and Het mice in the percentage of
splenic Th17, Th1, and Th2 cells (Figures 6(a)–6(c)), whereas
the percentage of splenic Treg cells was increased in Het mice
compared to bothWt and Fads1Null (𝑃 = 0.008, Figure 6(d)).
3.7.The Colonic Mucosal Cytokine Microenvironment Is Modi-
fied in aManner Consistent with ReducedTh17 Cell Activation
in Fads1Null Mice. The mRNA expression levels of key
cytokines and transcription factors related to specific T cell
subsets and inflammatory status in the colons of TNBS-
treated Fads1 mice are shown in Table 4. mRNA levels
did not differ between Wt and Het mice for any genes
except the Th1 cell master transcription factor Tbet, which
was reduced in both Het and Null mice compared to Wt
(𝑃 = 0.004). Additionally, mRNA expression of the Th17
cell master transcription factor ROR𝛾𝜏 was reduced in Fads1
Null mice compared to Wt (𝑃 = 0.03). Further, in Fads1 Null
mice, mRNA levels of the Th17 cell signature cytokines, IL-
17A and IL-17F, and IL-23, which maintains an established
Th17 cell phenotype, were all reduced compared to Wt (𝑃 <
0.05). mRNA levels of the inflammatory mediator IL-6 were
also reduced in Fads1 Null mice compared to Wt (𝑃 <
0.05). Collectively, these data indicate that, in mice devoid
of AA-derived eicosanoids, colonic mRNA levels of Th17 cell
related cytokines and transcription factors are suppressed
following TNBS treatment, coinciding with an improved
clinical outcome in Fads1 Null mice.
4. Discussion
In the TNBS colitis model, PGE
2
has been shown to exac-
erbate colonic inflammatory processes and colitis severity
through activation of the IL-23/IL17 axis and by increasing
local Th17 cell numbers [18, 25, 30, 31]. Moreover, PGE
2
coordinates locally with cytokines present within the tissue
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Figure 3: Percentage of mesenteric lymph node (MLN) CD4+ T cell subsets inWt and Fat-1 TNBS-treated mice (black bars, 𝑛 = 9–12 pooled
samples/genotype comprised of 2–4 MLNs) and saline controls (grey bars, 𝑛 = 4 pooled samples/genotype). (a) Th17 cells (CD4+ IL-17A+),
(b)Th1 cells (CD4+ IFN𝛾+), (c)Th2 cells (CD4+ IL-4+), and (d) Tregs (CD4+ Foxp3+). Data were analyzed by two-way ANOVA (main effects:
genotype and treatment); bars represent means ± SEM. Bars not sharing a symbol differ (𝑃 ≤ 0.05).
microenvironment to directly promote Th17 cell differenti-
ation and effector function [18, 26–29]. Further, other n-6
PUFA-derived eicosanoids have also been shown to promote
Th17 cell development [32]. In Fat-1 mice (Table 1), levels
of n-6-derived eicosanoids were reduced and n-3 PUFA-
derived PGE
3
levels were increased compared to Wt litter-
mates. Additionally, in Fads1 Null mice, the biosynthesis of
AA-derived eicosanoids was reduced (Table 2) and colonic
mucosal PGE
2
levels were negligible compared to Wt. Inter-
estingly, despite the different mechanisms through which
colonic tissue AA-derived eicosanoid levels, including PGE
2
,
were antagonized in the two genetic mouse models utilized
in this study, the TNBS-induced inflammatory phenotype
observed in both models was similar. This highlights the
critical role which PGE
2
and other AA-derived eicosanoids
may be playing in activating inflammatory T cell subsets
and perpetuating colitis-associated inflammation and dis-
ease severity. In both mouse models (Fat-1 transgenic and
Fads1 Null mice), colonic mucosal AA-derived eicosanoid
levels were reduced (Tables 1 and 2), colon injury scores
improved (Figures 1(d) and 5(d)), the percentage of splenic
inflammatory Th17 cells was decreased (Figures 4(a) and
6(a)), and colonic mucosal mRNA expression of Th17 cell
markers and inflammatorymediators (IL-17A, ROR𝛾𝜏, IL-23,
and MCP-1) were reduced (Tables 3 and 4). Further, in both
models, loss of AA-derived eicosanoids was accompanied by
reducedTh17 cell numbers and a remodeled colonic mucosal
gene expression profile that was consistent with suppressed
inflammatory potential andTh17 cell polarization, activation,
and maintenance [2, 9, 57, 58, 61–65]. These changes coin-
cided with reduced TNBS-induced mucosal injury, thereby
demonstrating the critical roleswhichAAand itsmetabolites,
for example, PGE
2
, andTh17 cells play in perpetuating TNBS
colitis severity. The similarities between the two models
support the conclusion that the combination of inflamma-
tory cytokines and noncytokine immunomodulators (i.e.,
AA-derived eicosanoids) present in the local inflammatory
microenvironment during T cell differentiation and activa-
tion determines the ultimate phenotype of Th17 cells, as
previously demonstrated in the TNBS model [26].
Enriched n-3 PUFA tissue levels in Fat-1 mice [46]
corresponded to reduced colitis severity and the decreased
percentages of proinflammatory Th17 and Th1 cells within
the colon lamina propria (Figures 2(a) and 2(b)), the MLN
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Figure 4: Percentage of splenic CD4+T cell subsets in Wt and Fat-1 TNBS-treated mice (black bars, 𝑛 = 10–12 spleens/genotype) and saline
controls (grey bars, 𝑛 = 4/genotype). (a) Th17 cells (CD4+ IL-17A+), (b) Th1 cells (CD4+ IFN𝛾+), (c) Th2 cells (CD4+ IL-4+), and (d) Tregs
(CD4+ Foxp3+). Data were analyzed by two-way ANOVA (main effects: genotype and treatment). Bars represent means ± SEM. Bars not
sharing a symbol differ (𝑃 ≤ 0.05).
(Figures 3(a) and 3(b)), and the spleen (Figures 4(a) and
4(b)). These results demonstrate that the activation and/or
polarization of T cell subsets known to drive IBD [1–4]
are directly antagonized by n-3 PUFA both locally and
systemically. Conversely, the percentages of Tregs and Th2
cells were unaffected (Figures 2–4), indicating that the ben-
eficial effect of n-3 PUFA was likely not due to enhanced
Treg function or a shift in polarization from Th1 to Th2
cells. Interestingly, in Fat-1 mice, changes in the colonic
gene expression profile were consistent with reduced Th17
cell activation, proliferation, maintenance, and inflammatory
capacity [57, 63, 65] evidenced by reduced expression of IL-
17A, IL-21, IL-23, MCP-1, IL-1𝛽, and TNF𝛼 (Table 3) and
increased expression of the Th17 cell-antagonizing cytokine,
IL-27, and the anti-inflammatory cytokine, IL-10.
In Fads1Null mice, due to the limitations in cell numbers,
only splenic T cell subsets, representative of the systemic
response, were assessed and the percentages ofTh17,Th1, and
Th2 cells were reduced compared to Wt littermates (Figures
6(a)–6(d)). Interestingly, the percentage of splenic Tregs was
not affected in Fads1 Null mice compared to Wt and was
actually elevated in Het mice (Figure 6(d)), indicating that
not all CD4+ T cell effector subsets are reduced in Fads1
Null mice, as regulatory capabilities appear to be sustained.
Moreover, the percentage of all T cell subsets detected in
Fads1 Null saline control treated mice did not differ from
either Wt or Het, indicating that the subsequent TNBS-
induced reductions in cell numbers observed in Fads1 Null
mice were not a byproduct of reduced splenic T cell numbers
or activation. The reduced percentage of splenic Th17 and
Th1 cells in Fads1 Null mice coincided with reduced colonic
AA-derived eicosanoid levels including PGE
2
(Table 1) and
reduced colonic injury scores (Figure 5(d)). Interestingly,
both the Fat-1 and Fads1 Null TNBS-treated mice exhibited
suppressed IL-17A, IL-23, and ROR𝛾𝜏 colonic mRNA levels
compared to Wt littermate controls, consistent with reduced
inflammation andTh17 cell polarization, function, andmain-
tenance (Tables 3 and 4) [57, 63, 65]. Collectively, themucosal
gene expression data indicate that the local percentage of
activatedTh17 cells in the colon in response to TNBS-induced
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Table 3: ColonicmucosalmRNA expression inWt and Fat-1TNBS-
treated mice1.
Gene Wt Fat-1
IL-17A 6.54 ± 2.95 2.04 ± 0.73∗
IL-17F 6.14 ± 1.33 5.96 ± 1.03
IL-21 0.63 ± 0.09 0.15 ± 0.07∗
IL-22 0.48 ± 0.17 0.95 ± 0.32
IL-23 1.63 ± 0.42 1.01 ± 0.41
IL-23R 1.72 ± 0.44 1.76 ± 0.28
IL-27 3.68 ± 0.84 7.50 ± 1.49∗
CCL20 4.93 ± 1.59 4.25 ± 0.61
CCR6 0.45 ± 0.97 0.7 ± 0.48
ROR𝛾𝜏 15.79 ± 1.29 12.25 ± 0.82∗
Tbet 2.30 ± 0.79 1.42 ± 0.46
Foxp3 1.74 ± 0.97 3.24 ± 0.63
IL-10 1.08 ± 0.68 2.64 ± 0.52∗
TGF𝛽1 5.56 ± 0.66 6.91 ± 2.26
MCP-1 8.34 ± 3.75 3.03 ± 0.58∗
IL-1𝛽 1.28 ± 0.87 0.39 ± 0.09∗
TNF𝛼 1.90 ± 1.3 0.73 ± 0.18∗
IL-6 2.88 ± 0.86 2.66 ± 0.61
IFN𝛾 0.63 ± 0.22 0.34 ± 0.15
IL-4 0.20 ± 0.11 0.28 ± 0.25
1Mean values ± SEM of TNBS-treated Wt and Fat-1 mice (𝑛 = 8–
10/genotype). All genes were measured within the same samples and
expression was normalized to ribosomal 18S (in arbitrary units). For each
gene, values marked with an asterisk differ fromWt (𝑃 ≤ 0.05).
colitis was likely also reduced in the Fads1Nullmouse, similar
to the outcome in the Fat-1 mouse, although future studies
confirming this interpretation are required.
AA is enriched in the membrane phospholipids of cells
involved in the inflammatory response, and therefore, this
fatty acid serves as the major precursor for eicosanoid medi-
ators [66], which modulate both the intensity and duration
of inflammatory responses [67].The AA-derived eicosanoids
have been shown to exert largely proinflammatory effects,
although some anti-inflammatory effects have been reported
[66, 67]. Ultimately, the eicosanoid profile and resulting
functional outcome are contextually dependent upon the
cell types present within the tissue microenvironment and
the nature of the inflammatory stimulus. In this study, we
showed that antagonism of AA-derived eicosanoids (specif-
ically PGE
2
) by two distinct mechanisms results in fewer
proinflammatory Th1 and Th17 cells both in local colitis-
associated tissue sites and, systemically, a remodeled colonic
phenotype consistent with reduced Th17 cell activation and
maintenance, and reduced TNBS-induced mucosal damage
and disease severity. PGE
2
-mediated reduction of mucosal
damage has been reported in the dextran sodium sulfate-
(DSS-) induced acute colitis model [68, 69]. This beneficial
effect may be mediated through the EP4 receptor [70, 71]
and is likely attributable to the ability of PGE
2
to stimulate
epithelial cell proliferation in the presence of DSS [72].
However, Fads1Null mice, which are devoid of PGE
2
, exhibit
reduced viability in response to DSS and are unable to
Table 4: Colonic mucosal mRNA expression in Wt, Het, and Null
Fads1 TNBS-treated mice1.
Gene Wt Het Null
IL-17A 7.62 ± 4.70∗ 1.10 ± 0.32‡ 0.31 ± 0.01‡
IL-17F 12.95 ± 3.71∗ 5.46 ± 1.07‡ 4.19 ± 0.98‡
IL-21 1.53 ± 0.80 0.70 ± 0.18 0.47 ± 0.14
IL-22 1.48 ± 1.05 0.44 ± 0.33 0.10 ± 0.10
IL-23 3.88 ± 0.43∗ 3.58 ± 0.57∗‡ 2.19 ± 0.39‡
IL-23R 0.73 ± 0.16 0.40 ± 0.05 0.65 ± 0.21
IL-27 2.75 ± 0.67 1.86 ± 0.42 1.80 ± 0.46
CCL20 1.42 ± 0.49 1.36 ± 0.57 1.13 ± 0.30
CCR6 1.22 ± 0.38 0.82 ± 0.24 0.91 ± 0.44
ROR𝛾𝜏 11.07 ± 2.04∗ 8.75 ± 1.34∗ 5.28 ± 0.17‡
Tbet 8.35 ± 1.32∗ 3.30 ± 0.66‡ 4.12 ± 0.69‡
Foxp3 2.95 ± 0.65 2.52 ± 0.23 1.81 ± 0.27
IL-10 13.57 ± 3.91∗ 9.08 ± 2.77∗ 3.95 ± 1.38‡
TGF𝛽1 1.80 ± 0.27 1.68 ± 0.26 1.31 ± 0.13
MCP-1 25.57 ± 8.37∗ 32.41 ± 14.00∗ 8.86 ± 3.49‡
IL-1𝛽 44.13 ± 12.57 31.30 ± 13.19 24.51 ± 12.95
TNF𝛼 9.85 ± 1.81 9.89 ± 3.82 5.65 ± 1.72
IL-6 11.54 ± 4.07∗ 7.11 ± 3.34∗‡ 2.10 ± 0.73‡
IFN𝛾 1.89 ± 1.01 0.52 ± 0.16 0.62 ± 0.21
IL-4 0.64 ± 0.36 nd 0.38 ± 0.73
1Mean values ± SEM of TNBS-treated Wt, Het, and Null Fads1 mice (𝑛 =
6–9/genotype). All genes were measured within the same samples and
expression was normalized to ribosomal 18S (in arbitrary units). For each
gene, values not sharing a superscript symbol differ between genotypes (𝑃 ≤
0.05). nd, not detected.
stimulatemucosal repairmechanisms [48]. Since DSS is toxic
to the gut epithelial cells and affects the integrity of the
mucosal barrier [49], it is more appropriately utilized as a
mucosal wounding model, which is further supported by the
lack of adaptive immune system involvement in the acute
phase [73], thereby questioning the applicability of the DSS
model to human IBD.
Conversely, the TNBS colitis model recapitulates many
of the macroscopic and histological characteristics of human
IBD [74, 75]. CD4+ T cell activation/tissue accumulation
is a key feature of the immunopathology [49, 74, 75], and
specifically, the Th17 cell subset has been shown to drive the
inflammatory pathology [23]. Moreover, inhibition of CD4+
T cells via CD4 mimetics or anti-CD4 monoclonal antibody
prevents disease development [76]. Administration of 16,16-
dimethyl prostaglandin E
2
or Enprostil (PGE
2
analogue) to
TNBS-treated rats has been shown to acutely reduce histo-
logical damage scores and myeloperoxidase activity [77, 78],
although these effects are not sustained for longer durations
after exposure [78]. However, Th17 cell activation and Th17
cell driven inflammation mediated by PGE
2
during TNBS-
induced colitis have been documented previously [18, 26–29].
Other AA-derived eicosanoids may play a contributing role
to the activation of Th17 cells as documented elsewhere [32].
Therefore, future studies investigating the specific contribu-
tions of other n-6-derived eicosanoids are warranted. The
effects of PGE
2
are mediated through receptors (EP1-EP4),
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Figure 5: Distal colon histological injury/damage scores assessed in Wt, Het, and Null Fads1 TNBS-treated mice (𝑛 = 8–10/genotype) in a
blinded manner by a board-certified pathologist (B. Weeks). ((a)–(c)) Representative images (100x magnification, scale bar = 100 𝜇m) of Wt,
Het, andNull Fads1TNBS-treated distal colons, respectively. (d) Distal colon injury scores (0–3). Data were analyzed using the Kruskal-Wallis
test (𝑃 ≤ 0.05) followed byWilcoxon two-sample testing. Median values are shown and significant differences between genotypes are marked
by an asterisk (𝑃 ≤ 0.05).
which are expressed on multiple cell types [79] including
T cells, dendritic cells [25, 26, 28], and the colonic mucosa
[80]. Previous data indicate that the PGE
2
-dependent effect
onTh17 cells is meditated through the EP2 and EP4 receptors
[25, 26, 29], suggesting that antagonism of these receptors
could be a potential therapeutic target for IBD treatment,
although future studies are required.
In conclusion, our observations demonstrate the utility
of antagonizing colonic AA-derived eicosanoids as a mech-
anism to reduce inflammatory T cell activation and improve
colitis-associated immunopathology. Moreover, these results
suggest that dietary n-3 PUFA could be used alone, or as
an adjunctive therapy, in improving the clinical outcome of
colonic mucosal Th17 cell-mediated pathologies.
Abbreviations
IBD: Inflammatory bowel disease
CD: Crohn’s disease
FO: Fish oil
PUFA: Polyunsaturated fatty acids
EPA: Eicosapentaenoic acid
DHA: Docosahexaenoic acid
Tregs: Regulatory T cells
TNBS: 2,4,6-Trinitrobenzene sulfonic acid
PGE
2
: Prostaglandin E
2
PG: Prostaglandin
TX: Thromboxane
HODE: Hydroxyl-octadecadienoic acid
HETE: Hydroxyl-eicosatetraenoic acid
AEA: Arachidonoyl ethanolamine
AG: Arachidonoyl glycerol
DSS: Dextran sodium sulfate.
Conflict of Interests
The authors declare that there is no conflict of interests.
Mediators of Inflammation 11
‡ ‡
0
1
2
3
4
5
6
Wt Het Null
CD
4
+
IL
-1
7
A
+
ce
lls
 (%
)
∗
∗ ∗
∗
(a)
‡
‡
0
2
4
6
8
Wt Het Null
∗ ∗
∗
CD
4
+
IF
N
𝛾
+
ce
lls
 (%
)
§
(b)
‡
‡
0
1
2
3
4
5
6
Wt Het Null
∗
∗ ∗
∗
CD
4
+
IL
-4
+
ce
lls
 (%
)
Saline
TNBS
(c)
‡
0
1
2
3
4
5
Wt Het Null
∗
∗
∗
∗
∗
CD
4
+
Fo
xp
3
+
ce
lls
 (%
)
Saline
TNBS
(d)
Figure 6: Percentage of splenic CD4+ T cell subsets in Wt, Het, and Null Fads1 TNBS-treated mice (black bars, 𝑛 = 6–9 mice/genotype) and
saline controls (grey bars, 𝑛 = 3-4 mice/genotype). (a) Th17 cells (CD4+ IL-17A+), (b) Th1 cells (CD4+ IFN𝛾+), (c) Th2 cells (CD4+ IL-4+),
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